Provided by Tiger Trade Technology Pte. Ltd.

Goldman Sachs Future Health Care Equity ETF

35.95
0.0000
Volume:11
Turnover:398.75
Market Cap:18.87M
PE:- -
High:35.95
Open:35.95
Low:35.95
Close:35.95
52wk High:38.66
52wk Low:31.32
Shares:525.00K
Float Shares:525.00K
Volume Ratio:0.18
T/O Rate:0.00%
Dividend:0.11
Dividend Rate:0.31%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Pharma Lobby Sues Trump Administration over Medicare Drug Price Cuts

Reuters
·
Oct 07

Guardant Health is Maintained at Overweight by Barclays

Dow Jones
·
Oct 07

Eli Lilly is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Oct 07

What Eli Lilly Stock's First Line Jaypirca Approval Means For Shareholders

Simply Wall St.
·
Oct 07

Halozyme Therapeutics Shares up 2% After Court Win Against Merck to Block Subcutaneous Keytruda in Select Markets

THOMSON REUTERS
·
Oct 07

AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays

GlobeNewswire
·
Oct 07

Morgan Stanley Adjusts Price Target on Merck to $177 From $179

MT Newswires Live
·
Oct 07

Tempus AI announces multi-year collaboration with Moderna, Merck

TIPRANKS
·
Oct 07

Halozyme announces Dutch court of the Hague found Merck infringed patents

TIPRANKS
·
Oct 07

Tempus Expands Multi-Year Collaboration with Moderna, Merck on V940 Melanoma Vaccine Commercialization Support

Reuters
·
Oct 07

Halozyme Therapeutics - Iv Version of Keytruda Remains Available and not Covered by Halozyme's Patent or Court Injunction

THOMSON REUTERS
·
Oct 07

Halozyme Therapeutics - Court Rejects Merck's Arguments That Ep622 Patent is Invalid

THOMSON REUTERS
·
Oct 07

Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda Sc in Multiple European Markets

THOMSON REUTERS
·
Oct 07

Halozyme Therapeutics - Court Orders Msd BV to Stop Keytruda Sc Manufacture and Sale in Eight European Countries

THOMSON REUTERS
·
Oct 07

Halozyme Therapeutics - Injunction Forbids Msd from Facilitating Infringement by Affiliates

THOMSON REUTERS
·
Oct 07

Tempus Announces Multi-Year Collaboration with Moderna and Merck

THOMSON REUTERS
·
Oct 07

Morgan Stanley Adjusts Price Target on Eli Lilly to $1,430 From $1,419

MT Newswires Live
·
Oct 07

Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease

GlobeNewswire
·
Oct 07

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Oct 07

AlzeCure Pharma to Present at Redeye Neurology Day

Reuters
·
Oct 07